• Better Screening for Prostate Cancer

    Impact Life Do What’s Right Innovate Together Build Community

  • The Problem

    Prostate Cancer is the second deadliest cancer for American men. More than 191,930 men will be diagnosed in 2020 and 33,330 will die from Prostate Cancer. Simultaneously, it is overdiagnosed and overtreated in men with indolent (less aggressive) prostate cancer. This leads to unnecessary treatments such as prostatectomy and radiation therapy.

    PSA: An Imperfect Screening Tool

    Prostate Specific Antigen or PSA is currently the standard test used for prostate cancer screening. However, it has several shortcomings, including:

    • PSA can be elevated for reasons other than Prostate Cancer.
    • PSA and its variants miss a large portion of aggressive Prostate Cancers.
    • PSA can’t distinguish between indolent and aggressive prostate cancers. Leading many patients to undergo unnecessary treatments.

    Screening is Declining

    Because the PSA test is no longer recommended, screening rates of men in the United States have declined. Lower screening reduces the overdiagnosis and overtreatment of Prostate Cancer as intended by the recommendation. However, by screening less men for Prostate Cancer, the aggressive cancers will also be missed. This will trigger more deaths that could have been avoided.

    Let's not abandon screening; let's build a better screening test.

  • OUR MISSION

    ● Impact Life ●

    We strive to make an impact on lives that can be saved, to have a positive impact on the lives of our patients, physicians, partners and employees.

    ● Do What's Right ●

    We will continue to always do whats right.
     

    ● Innovate Together ●
    We are building a better test to screen for and determine the aggressiveness of prostate cancer.

     

    ● Build Community ●

    Only with the community around us can we bring this screening test to the forefront and help more men get tested


     

  • The Solution

    Using seminal fluid as a sample source; develop a screening test that can accurately determine if an asymptomatic patient has no cancer, indolent cancer, or aggressive cancer.

    Why Seminal Fluid?

    The prostate produces about 30% of the total volume of seminal fluid; thus giving it the distinct advantage of having direct, non-invasive access to abundant prostate cancer biomarkers. These important biomarkers would be undetectable at the same stage of cancer development by other sample types such as blood or urine.
    Furthermore, our test will be available to be collected in the comfort of ones own home and shipped back to the lab. The ease of use and widespread availability of this test will allow more men to be tested and more affordably.

    The Seminal Fluid Advantage

    Over 250,000X more biomarker in Seminal Fluid than in blood serum.

    A Diverse Biomarker Panel

    A broad range of biomarkers have been described that are able to detect cancer and discriminate between indolent and aggressive cancer. Gregor utilizes a combination of
     

    Methylated DNA, proteins, and microparticles.
     

    Gregor leverages the most promising combination of these biomarkers and methods to screen for prostate cancer.

    Sample Stability

    Gregor has developed a proprietary system to maintain biomarker stability in the seminal fluid. This will allow samples to be collected in the comfort of the patient's home and shipped back to Gregor's laboratory. The sample stability system will allow the prostate cancer screening test to be used by men in even the most remote areas.

All Posts
×